Literature DB >> 1702158

Induction of chronic human immunodeficiency virus infection is blocked in vitro by a methylphosphonate oligodeoxynucleoside targeted to a U3 enhancer element.

J Laurence1, S K Sikder, J Kulkosky, P Miller, P O Ts'o.   

Abstract

Oligodeoxynucleosides with internucleoside methylphosphonate linkages complementary to regions within U3 of human immunodeficiency virus type 1 were evaluated for their ability to block phorbol myristate acetate upregulation of virus in chronically infected promonocytic and T-lymphoblastoid cell lines. One such oligomer, targeted to an NF-kappa B enhancer element, inhibited phorbol myristate acetate induction of viral replication and tat-mediated trans activation of the human immunodeficiency virus long terminal repeat. The effect of this construct is contrasted with classical antisense methylphosphonate-derivatized oligomers complementary to initiation codon and splice acceptor sites of human immunodeficiency virus structural and regulatory genes. Its activity suggests a novel application of the modified oligonucleotide strategy in the blockade of viral induction from latently infected cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1702158      PMCID: PMC240507     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Sugar modified oligonucleotides. I. Carbo-oligodeoxynucleotides as potential antisense agents.

Authors:  M Perbost; M Lucas; C Chavis; A Pompon; H Baumgartner; B Rayner; H Griengl; J L Imbach
Journal:  Biochem Biophys Res Commun       Date:  1989-12-15       Impact factor: 3.575

2.  Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.

Authors:  C Southgate; M L Zapp; M R Green
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

3.  A catalogue of splice junction sequences.

Authors:  S M Mount
Journal:  Nucleic Acids Res       Date:  1982-01-22       Impact factor: 16.971

4.  Characterization of the African HIV-1 isolate CBL-4 (RUT) by partial sequence analysis and virus neutralization with peptide antibody and antisense phosphate-methylated DNA.

Authors:  J Goudsmit; J Geelen; W Keulen; D Notermans; C Kuiken; C Ramautarsing; L Smit; L Koole; M van Genderen; H Buck
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

5.  Cytomegalovirus activates transcription directed by the long terminal repeat of human immunodeficiency virus type 1.

Authors:  P A Barry; E Pratt-Lowe; B M Peterlin; P A Luciw
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates.

Authors:  P S Sarin; S Agrawal; M P Civeira; J Goodchild; T Ikeuchi; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

7.  Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.

Authors:  S Agrawal; J Goodchild; M P Civeira; A H Thornton; P S Sarin; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

8.  Effect of tamoxifen on regulation of viral replication and human immunodeficiency virus (HIV) long terminal repeat-directed transcription in cells chronically infected with HIV-1.

Authors:  J Laurence; H Cooke; S K Sikder
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

9.  Phosphate-methylated DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity.

Authors:  H M Buck; L H Koole; M H van Genderen; L Smit; J L Geelen; S Jurriaans; J Goudsmit
Journal:  Science       Date:  1990-04-13       Impact factor: 47.728

10.  Phosphoroselenoate oligodeoxynucleotides: synthesis, physico-chemical characterization, anti-sense inhibitory properties and anti-HIV activity.

Authors:  K Mori; C Boiziau; C Cazenave; M Matsukura; C Subasinghe; J S Cohen; S Broder; J J Toulmé; C A Stein
Journal:  Nucleic Acids Res       Date:  1989-10-25       Impact factor: 16.971

View more
  9 in total

1.  Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures.

Authors:  R V Giles; D M Tidd
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

Review 2.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

3.  Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides.

Authors:  I Demirhan; O Hasselmayer; D Hofmann; A Chandra; F P Svinarchuk; V V Vlassov; J Engels; P Chandra
Journal:  Virus Genes       Date:  1995-01       Impact factor: 2.332

4.  Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element.

Authors:  G Li; J Lisziewicz; D Sun; G Zon; S Daefler; F Wong-Staal; R C Gallo; M E Klotman
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

5.  Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element.

Authors:  T Vickers; B F Baker; P D Cook; M Zounes; R W Buckheit; J Germany; D J Ecker
Journal:  Nucleic Acids Res       Date:  1991-06-25       Impact factor: 16.971

6.  Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA.

Authors:  D Liu; J Donegan; G Nuovo; D Mitra; J Laurence
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

7.  Modified antisense oligodeoxynucleotides against the splice acceptor site of tat do not inhibit in vitro hematopoietic colony growth in HIV-positive patients.

Authors:  R G Geissler; J Muth; A Maurer; U Mentzel; M Mag; J W Engels; D Hoelzer; A Ganser
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

8.  The Ras-Raf pathway is activated in human immunodeficiency virus-infected monocytes and particpates in the activation of NF-kappa B.

Authors:  L Folgueira; A Algeciras; W S MacMorran; G D Bren; C V Paya
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Protein kinase C-zeta mediates NF-kappa B activation in human immunodeficiency virus-infected monocytes.

Authors:  L Folgueira; J A McElhinny; G D Bren; W S MacMorran; M T Diaz-Meco; J Moscat; C V Paya
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.